Warning letter · FDA Warning Letters

New Sun Inc.: FDA Warning Letter 626254 (Jun 8, 2022)

Agency action: Jun 8, 2022Record ID: fda_warning_-23198ab9d1604e4d
View official source ↗

What happened

Original notice title

New Sun Inc. MARCS-CMS 626254, June 08, 2022

From the archived source record

The Agency is particularly concerned that you market one of your unapproved new drug products as safe for children. For example, children may be at greater risk for adverse reactions associated with certain drug products due to differences in the ability of children to absorb, metabolize, distribute, or excrete such drug products or their metabolites. Unapproved New Drugs Based on our review of your website and product labeling (brochures), your New Sun products are drugs under section 201(g)(1) of the Act [21 U.S.C. 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, Advanced Liver Plus, Advanced U-Tract, Calcium Magnesium Liquid, Lymphatic Cleanser, Ultra CBD Oil (Hemp Oil), CBD Gummies, Advanced CBD Oil (Hemp Oil), NKC, and Kidz DHA fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)]. This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
2b6cefe357cd

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
New Sun products; Advanced Liver Plus; Supplements for Respiratory Health; Supplements for Circulatory Health; Supplements for Urinary Health; Kidz DHA; Kidz Super Dophilus; Ultra CBD Oil (Hemp Oil); CBD Gummies; and Advanced CBD Oil (Hemp Oil) products as dietary supplements; and Advanced CBD Oil (Hemp Oil); which you represent as containing cannabidiol (CBD) (hereinafter referred to as “New Sun products”); webpage for Advanced CBD Oil (Hemp Oil) states
Company
New Sun Inc.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.